Mania News and Research

RSS

Family history points to more severe bipolar disorder

A family history of mood disorders is associated with more severe symptoms at presentation and a poorer clinical course in patients with bipolar disorder, show findings from the STEP-BD study.

2 Jan 2014

DSM-5 mania duration criterion questioned

Researchers believe that the DSM 4-day duration criterion for diagnosing bipolar II disorder is no longer valid and its continued use could exclude a large number of patients with true bipolar II disorder.

5 Dec 2013

Bipolar-specific disease management gives good returns

Diagnostic-specific management of bipolar II disorder is associated with significant clinical improvements, show findings that support the need for greater recognition of the condition.

4 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Support for personal recovery concept in bipolar disorder

Researchers have found that “respect, hope, and self-empowerment” is a key psychosocial factor in the personal recovery of adults with bipolar disorder.

27 Nov 2013

Conversion from psychotic depression to bipolar disorder explored

Danish researchers have identified a range of characteristics in people with psychotic depression that predict an increased risk for conversion to bipolar disorder.

21 Nov 2013

Men’s cognitive advantage maintained in early bipolar disorder

Patients in the early stages of bipolar disorder show the same gender differences in cognitive functioning as mentally healthy individuals, findings from the STOP-EM trial show.

14 Nov 2013

Mood disorder subtypes remain in the family

Psychosis, mania, and depression are unlikely to have shared hereditary causes, report researchers in Molecular Psychiatry.

8 Nov 2013

Bipolar mania and depression independently inherited

Bipolar mania and depression may be independently inherited in families, findings of a US study suggest.

7 Nov 2013

Bipolar primary care prevalence varies by assessment method

The prevalence of bipolar disorder in primary care varies considerably according to the assessment method used, study findings suggest.

6 Nov 2013

First-episode type predicts morbidity, disease course in bipolar disorder

Study findings suggest that the type of first episode in patients with bipolar disorder can predict the type and degree of future morbidity, as well as the disease course.

5 Nov 2013

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

‘Distinct’ bipolar pathways revealed

A genetic analysis reported in Nature suggests two mechanisms that could lead to bipolar disorder.

25 Oct 2013

Mixed state impedes remission in bipolar depression

Researchers highlight the importance of identifying sub-syndromal manic symptoms in patients experiencing an episode of bipolar depression after finding these less prominent symptoms lengthen the time to remission.

17 Oct 2013

High bipolar medication adherence not elusive

Researchers have found “remarkably” high medication adherence rates among patients with bipolar disorder participating in a comparative effectiveness trial.

9 Oct 2013

Affective dimensions aid bipolar disorder diagnosis

Measuring affective dimensions can help clinicians diagnose bipolar disorder in patients with first-episode psychosis, researchers report.

3 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013